Use of lacosamide in children: experience of a tertiary medical care center in Brazil

Background Lacosamide (LCM) is a third-generation anti-seizure drug approved in Europe and the United States, either as a monotherapy or adjunctive therapy, to treat partial-onset seizures in adults, adolescents, and children. In Brazil, LCM is licensed for treatment only in patients older than 16 y...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Arquivos de Neuro-Psiquiatria
المؤلفون الرئيسيون:	Tayla Taynan Romão, Abraão Iuri Medeiros Angelim, Henrique Jannuzzelli Pires do Prado, Fernanda Veiga de Goes, Maria Elisa Paiva Pires, Rosiane da Silva Fontana, Lais de Carvalho Pires, Alexandre Ribeiro Fernandes, Isabella D'Andrea-Meira
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Thieme Revinter Publicações 2022-11-01
الموضوعات:	epilepsy lacosamide child drug resistant epilepsy pediatric assistants
الوصول للمادة أونلاين:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1758366